‘Ticking away in the back of my mind’: what does it mean to know the risk embedded in your DNA?
By Sophie Black,
The Guardian
| 09. 04. 2022
Mortality has always been on Perry Jones’ mind, much more so than your average 20-something. She’s dealt with a number of challenging health conditions since her teens, so when her mother urged her to be screened for the BRCA1 variant and BRCA2 variant gene a couple of years ago (both of which indicate a high risk of breast and ovarian cancer) she didn’t exactly jump at the chance.
Jones, who has type 1 diabetes, coeliac disease and spinal development issues, speaks about her dealings with the health system in the world-weary way of someone who’s been in and out of waiting rooms her whole life.
“I’ve got the whole wazoo. So a part of me was like, ‘What’s the likelihood that I’m going to have another thing? It’ll be fine. There’s no point.’”
But Jones’ mother insisted. After all, she’d been diagnosed with breast cancer at the age of 40. “Mum said it’s better to know than not to know. And if we know, then we can warn others in our family and we can look into better treatment methods...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...